Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

ONCURIOUS NV Receives Project Grant from VLAIO to Progress its Pipeline of Next Generation Cancer Immunotherapies

11 Jun 2019

Leuven, Belgium 11 June 2019 – ONCURIOUS NV, a Belgium-based biotech company focusing on the development of innovative oncology treatments, today announces that it has received from Flanders Innovation and Entrepreneurship (VLAIO) a project grant of close to €1 million to support the further pre-clinical development of its pipeline of next generation cancer immunotherapies. Oncurious will do this in close collaboration with VIB Discovery Sciences, steered by the scientific input of the VIB founding labs.

This non-dilutive grant funding will be used to identify a number of multi-specific biologics with distinct modes of action against immunomodulatory targets. These candidates will then be assessed in pre-clinical tumor models, both as monotherapies and in combination with standard of care treatment. The funds will also support the further development of Oncurious, including the recruitment of several scientists.

Patrik De Haes, MD, Executive Chairman of ONCURIOUS NV comments, “We are delighted by the potential of our pipeline of next generation immunotherapies and this project grant will provide us with funding to generate and select the most appropriate candidates to take further into pre-clinical development. We believe that the development of our immunotherapy pipeline, will in time, be an important source of value for Oncurious’ shareholders.”

Johan Cardoen, PhD, Managing Director of VIB comments, “We are pleased that VLAIO has recognized the compelling science behind our portfolio of next-generation immunotherapies for the treatment of cancer. This grant funding will enable Oncurious to hire scientists and conduct a range of experiments designed to provide the data needed to select the most appropriate novel immuno-oncology assets for further development.”

Press release attachment: